<DOC>
	<DOCNO>NCT02311673</DOCNO>
	<brief_summary>The purpose study evaluate effect daily subcutaneous ( SC ) injectable formulation RM-493 obese subject Prader-Willi syndrome tolerability , weight loss hyperphagia-related behavior . The study drug ( RM-493 placebo ) administer blinded fashion . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Ph 2 Trial Evaluate Safety &amp; Efficacy RM-493 Obese Patients With Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<criteria>1 . PWS due chromosome 15 microdeletion , maternal uniparental disomy , imprint defect , confirm fluorescent situ hybridization , chromosomal microarray , and/or methylation study . Obese male female volunteer weigh least 50 kg BMI ≥27 kg/m² 2 . Age 1665 year 3 . If volunteer diagnosis type 2 diabetes , follow criterion must meet : 1 . HbA1c &lt; 7.5 % manage insulin . Patients take GLP1 analogue ( exenatide liraglutide ) must stable dose great 3 month . 2 . Fasting plasma glucose &lt; 140 mg/dL 3 . No history ketoacidosis hyperosmolar coma 4 . Vital sign must within follow range stable . 1 . Systolic blood pressure , 90150 mm Hg 2 . Diastolic blood pressure , 5090 mm Hg 3 . Pulse rate , 40100 bpm 5 . Stable body weight home ~2 month ( self guardianreported loss/gain within ± 5 % ) . 6 . Blood pressure ( ≤150/90 mmHg ) ; may include stable dose ( ≥ 30 day use ) two antihypertensive medication intend remain stable dose protocol 7 . Parent guardian able communicate well investigator , understand comply requirement study , able understand sign write informed consent . Due significant intellectual disability PWS , assent provide patient consent . 8 . Results screen clinical laboratory test ( CBC differential platelet chemistry profile ) must within normal range , outside normal range , must accept investigator sponsor clinically significant . 9 . Females nonchildbearing potential , define surgically sterile ( status post hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) postmenopausal least 12 month ( confirm screen FSH level postmenopausal lab range ) , require contraception study . All female childbearing potential must agree use contraception outline protocol . 10 . Males female partner childbearing potential must agree double barrier method become sexually active study 90 day follow study . Male subject must donate sperm 90 day follow participation study . 11 . Patients must stable dose allow chronic concomitant medication participate study , describe protocol . This defined change medication least 60 day prior Day 1 change dose least 30 day prior Day 1 ; Note stable concomitant usage ( &gt; 3 month ) growth hormone , hormone replacement therapy , GLP1 agent , statin , medication ( exclude insulin , modafinil , antipsychotic ) , medication commonly use PWS patient allow ( See Section 6.4.5 Concomitant medication ) . 1 . Recent use ( within 3 month ) weight loss agent include herbal medication . 2 . Diagnosis schizophrenia , bipolar disorder , personality disorder DSMIII disorder investigator believe interfere significantly study compliance . 3 . A PHQ9 score ≥15 . 4 . Any suicidal ideation type 4 5 CSSRS . 5 . Clinically significant illness 8 week screen . 6 . History clinically significant bleeding disorder . 7 . Current , clinically significant liver , renal , pulmonary , cardiac , oncologic , GI disease . 8 . Diagnosis type 1 diabetes mellitus active endocrine disorder ( e.g. , Cushing syndrome , thyroid dysfunction except adequate thyroid glucocorticoid replacement supplement ) . 9 . Cardiovascular disease event include history CHF , coronary artery disease , MI , second degree great heart block prolong QT syndrome . 10 . Blood pressure &gt; 150/90 mmHG . 11 . Liver disease liver injury indicate abnormal liver function test , SGOT ( AST ) , alkaline phosphatase , serum bilirubin ( &gt; 1.5 x ULN test ) history hepatic cirrhosis . 12 . History presence impair renal function indicate clinically significantly abnormal creatinine , BUN , urinary constituent ( e.g. , albuminuria ) moderate severe renal dysfunction define Cockroft Gault equation ( &lt; 50 mL/min ) . 13 . History close family history ( parent sibling ) melanoma . 14 . Oculocutaneous albinism ( occurs ~1 % PWS ) . 15 . Significant dermatologic finding part Screening comprehensive skin evaluation perform dermatologist . Any concern lesion identify screening period biopsied result know benign prior randomization . If pretreatment biopsy result concern , patient exclude study . 16 . Significant history abuse drug solvent year screen positive Drugs Abuse ( DOA ) test screening . 17 . History alcohol abuse past year screen currently drink excess 21 unit per week ( 3 serving units/day ) . 18 . Caffeine consumption exceed 6 cup caffeinated tea/coffee ( equivalent ) per day . 19 . Volunteer , opinion Investigator , suitable participate study . 20 . Participation clinical study investigational drug/device within 3 month prior first day dose . 21 . Positive history human immunodeficiency virus ( HIV ) , Hepatitis B Hepatitis C test tuberculosis . 22 . Serious adverse reaction significant hypersensitivity drug . 23 . Clinically significant blood loss blood donation &gt; 500 mL within 3 month . 24 . Inadequate venous access . 25 . History low blood count recur infection .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Prader-Willi Syndrome</keyword>
	<keyword>obesity</keyword>
	<keyword>hyperphagia</keyword>
</DOC>